Carmot Therapeutics Announces Completion of Acquisition by Roche
A week after one obesity biotech, Carmot Therapeutics, backed out of its IPO plans in favor of a $2.7 billion sale to Roche, another announced plans to go public on Nasdaq.
Roche joins race for obesity drugs with $2.7 billion Carmot deal
Roche to acquire Carmot for an upfront payment of $2.7 billion and the potential for $400 million in milestone payments Carmot will join the Roche Group as part of Roche™s Pharmaceuticals...
Carmot Therapeutics has filed to go public in a chilly environment for new listings, but the obesity biotech’s place in one of drug development’s hottest fields could buoy its chances of a successful IPO.
“ Randomized, placebo-controlled trial to assess 16-week treatment with CT-868 in participants with overweight or obesity with type 1 diabetes (T1D) “ “ A second mechanistic clinical trial is...
CT-388 administered once-weekly resulted in clinically meaningful weight loss and insulin sensitivity over a 4 week treatment period in participants with overweight or obesity without type 2...
BERKELEY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people with...
“ Phase 1 data for CT-388, a once-weekly injectable, dual GLP-1/GIP receptor agonist in development for the treatment of obesity and type 2 diabetes “ “ Phase 1b data for CT-868, a once-daily...
BERKELEY, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today...